ATE159174T1 - Verwendung eines gegen das 17-1a antigen gerichteten monoklonalen antikörpers zur herstellung eines arzneimittels für die behandlung von einem magen-darm-tumor - Google Patents

Verwendung eines gegen das 17-1a antigen gerichteten monoklonalen antikörpers zur herstellung eines arzneimittels für die behandlung von einem magen-darm-tumor

Info

Publication number
ATE159174T1
ATE159174T1 AT87306083T AT87306083T ATE159174T1 AT E159174 T1 ATE159174 T1 AT E159174T1 AT 87306083 T AT87306083 T AT 87306083T AT 87306083 T AT87306083 T AT 87306083T AT E159174 T1 ATE159174 T1 AT E159174T1
Authority
AT
Austria
Prior art keywords
antigen
monoclonal antibody
treatment
production
directed against
Prior art date
Application number
AT87306083T
Other languages
English (en)
Inventor
Hubert J P Schoemaker
Richard A Carrano
Original Assignee
Centocor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc filed Critical Centocor Inc
Application granted granted Critical
Publication of ATE159174T1 publication Critical patent/ATE159174T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT87306083T 1986-07-09 1987-07-09 Verwendung eines gegen das 17-1a antigen gerichteten monoklonalen antikörpers zur herstellung eines arzneimittels für die behandlung von einem magen-darm-tumor ATE159174T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88357286A 1986-07-09 1986-07-09

Publications (1)

Publication Number Publication Date
ATE159174T1 true ATE159174T1 (de) 1997-11-15

Family

ID=25382871

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87306083T ATE159174T1 (de) 1986-07-09 1987-07-09 Verwendung eines gegen das 17-1a antigen gerichteten monoklonalen antikörpers zur herstellung eines arzneimittels für die behandlung von einem magen-darm-tumor

Country Status (9)

Country Link
US (2) US6444207B1 (de)
EP (2) EP0252741B1 (de)
JP (2) JP2979318B2 (de)
AT (1) ATE159174T1 (de)
CA (1) CA1341281C (de)
DE (1) DE3752129T2 (de)
ES (1) ES2110392T3 (de)
GR (1) GR3025902T3 (de)
HK (1) HK1002829A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU643189B2 (en) 1988-09-06 1993-11-11 Xoma Corporation Production of chimeric mouse-human antibodies with specificity to human tumor antigens
EP0857176A1 (de) * 1995-10-25 1998-08-12 Centocor B.V. VON HUMANEM EPITHELANTIGEN Ep-CAM ABGELEITETE PEPTIDE UND IHRE ANWENDUNG
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
CA2327439C (en) * 1998-05-15 2005-07-05 Aphton Corporation Combination therapy for the treatment of tumors
MXPA01007148A (es) 1999-01-13 2002-03-27 Igeneon Krebs Immuntherapie Uso de anticuerpos para vacunacion anti-cancer.
HUP0302278A3 (en) 1999-04-15 2011-01-28 Pro Virus Treatment of neoplasms with viruses
JP2003505432A (ja) * 1999-07-23 2003-02-12 グラクソ グループ リミテッド 抗ｅｐ−ｃａｍ抗体と化学療法剤との組合せ
CA2441228A1 (en) 2001-03-23 2002-10-03 Aphton Corporation Combination treatment of pancreatic cancer
US20090191232A1 (en) 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
US20100311954A1 (en) * 2002-03-01 2010-12-09 Xencor, Inc. Optimized Proteins that Target Ep-CAM
CA2519294A1 (en) * 2003-03-24 2005-02-17 Wellstat Biologics Corporation Newcastle disease virus administration
JP4689597B2 (ja) 2003-03-28 2011-05-25 レセプター バイオロジックス インク． ガストリンホルモン免疫アッセイ
AT500650B1 (de) 2003-04-17 2009-11-15 Altropus Gmbh Immunogener rekombinanter antikörper
US20050084913A1 (en) * 2003-04-22 2005-04-21 Maxygen, Inc. Novel tumor-associated antigens
CA2580965C (en) 2004-09-22 2014-04-08 Receptor Biologix, Inc. Monoclonal antibodies to progastrin
US7557190B2 (en) 2005-07-08 2009-07-07 Xencor, Inc. Optimized proteins that target Ep-CAM
EP2044949A1 (de) 2007-10-05 2009-04-08 Immutep Verwendung von rekombinantem LAG-3 oder Derivaten daraus zur Auslösung einer Monozyten-Immunreaktion
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
JP6496529B2 (ja) * 2014-11-11 2019-04-03 株式会社Ｆｕｊｉ 特定方法、および特定装置
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
WO2017176380A1 (en) * 2016-02-22 2017-10-12 The General Hospital Corporation Systems and methods for selective targeting of structural features in treating skin conditions
JP7469225B2 (ja) 2017-06-15 2024-04-16 キャンサー アドヴァンシーズ インク． 腫瘍及び癌に対する体液性及び細胞性免疫を誘発するための組成物及び方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925922A (en) * 1983-02-22 1990-05-15 Xoma Corporation Potentiation of cytotoxic conjugates
US4579827A (en) * 1983-03-11 1986-04-01 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies to human gastrointestinal cancers and hybridoma method of production of the monoclonal antibodies
EP0199141A3 (de) * 1985-04-19 1988-07-20 Sloan-Kettering Institute For Cancer Research Monoklonale Antikörper gegen humanen Magen-Darmkrebs

Also Published As

Publication number Publication date
US6444207B1 (en) 2002-09-03
DE3752129D1 (de) 1997-11-20
JP2979318B2 (ja) 1999-11-15
EP0252741A3 (de) 1989-08-09
JP2000026312A (ja) 2000-01-25
JPS6360941A (ja) 1988-03-17
GR3025902T3 (en) 1998-04-30
CA1341281C (en) 2001-08-07
US20030072759A1 (en) 2003-04-17
EP0252741B1 (de) 1997-10-15
DE3752129T2 (de) 1998-05-07
ES2110392T3 (es) 1998-02-16
EP0755683A1 (de) 1997-01-29
JP3494592B2 (ja) 2004-02-09
HK1002829A1 (en) 1998-09-18
EP0252741A2 (de) 1988-01-13

Similar Documents

Publication Publication Date Title
ATE159174T1 (de) Verwendung eines gegen das 17-1a antigen gerichteten monoklonalen antikörpers zur herstellung eines arzneimittels für die behandlung von einem magen-darm-tumor
SE7503542L (de)
RU2008128244A (ru) Способы идентификации опухолей, восприимчивых к лечению антителами против erbb2
ATE27915T1 (de) Kovalente konjugate,die ein enzym und einen antikoerper verbinden und medikamentoese zubereitungen,die diese konjugate enthalten.
NZ210867A (en) Tumour-specific monoclonal antibodies, production thereof and use
DE3168595D1 (en) New para-substituted 3-phenoxy-1-alkylamino-propanol-2-s having beta receptor blocking properties
EP0194851A3 (de) Therapie der menschlichen Tumore
SE8404283L (sv) Anvendning av ett specifikt tumorassocierat antigen, nemligen sialosyllaktotetraos, for diagnostiska och terapeutiska forfaranden vid cancersjukdomar
PT81093A (de) Tumortherapeutikum und verfahren zu seiner herstellung
PT73112B (en) Process for preparing new substituted 3-phenoxy-1-alkoxy-carbonyl-alkylaminopropanol-2-s having beta receptor blocking properties
DK0531419T3 (da) Bistriazener som kemoterapeutiske midler
FR2536751B1 (fr) Nouveaux derives de tricyclophosphazenes, procede pour leur preparation et leur application en tant que medicament
IT8122035A0 (it) Composti di germanio, procedimento per la loro prparazione, procedimento per la preparazione di un farmaco mediante tali composti di germanio per il trattamento del cancro, nonche' medicinale finito cosi' ottenuto.
FR2416228A1 (fr) Sulfures de 4-pyrimidyle, leur procede de preparation et leur application en therapeutique
FR2354309A1 (fr) Nouveaux alcynols, leur procede de preparation et leurs applications en tant que medicaments
DE10210239A1 (de) Spezifische Ab1'-Antikörper gegen das Tumor-assoziierte Antigen CA125
AU5752490A (en) A novel tumor associated antigen
GB1173304A (en) A Process for the Manufacture of Benzoxadiaz[4,1,5]Ocines
UA10301A (uk) Спосіб лікуваhhя раку шлуhку
JPS56150018A (en) Prostaglandin-containing medicine
KR880006184A (ko) 2-클로로-4-((시아노메틸)티오)페닐 n-메틸 카바메이트
Szeberényi et al. Effect of 3-methylcholanthrene on nuclear subfractions in rat liver
Szmigielski et al. Intratumoral immunotherapy of advanced metastatic cancer with Propionibacterium granulosum KP-45
Thomson Human tumour immunity and characterization of the putative antigen
RU95120677A (ru) Способ лечения злокачественных опухолей

Legal Events

Date Code Title Description
EELA Cancelled due to lapse of time